A sustainable synthesis of the sars-cov-2 mpro inhibitor nirmatrelvir, the active ingredient in paxlovid

HIGHLIGHTS

• who: Joseph R. A. Kincaid from the University of have published the Article: A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid, in the Journal: (JOURNAL) of 17/08/2022

SUMMARY

Received @@

ACRONYMS

LAY DEFINITIONS

• Paxlovid: Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged oral medication used as a treatment for COVID-19. It contains the antiviral medications nirmatrelvir and ritonavir.In December 2021, nirmatrelvir/ritonavir was granted emergency use authorization by the United States Food . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.